Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Editas Medicine (EDIT): Analyst Average of $6 Implies +250% Upside From Current Levels

Editas Medicine (EDIT): Analyst Average of $6 Implies +250% Upside From Current Levels

Key Takeaways

  • The central target used here is $6, the arithmetic mean of roughly 11 verified analyst price targets, rounded from an average near $6.05.
  • That target sits far above the latest verified price of $1.71, implying a required move of roughly 250% — a very large gain.
  • Individual analyst targets span a wide range, from about $3 to $15, reflecting deep disagreement over EDIT-401's commercial potential and the company's cash runway.
  • Key supports include a stronger balance sheet, narrowing losses, promising preclinical and clinical data, and several recent upgrades and target increases.
  • Key risks include heavy cash burn, a pre-commercial pipeline, a high short interest, and the inherently uncertain path of gene-editing therapies.
  • For more detail on the ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

The $6 central target is not an official published consensus; it is a simple average of individual, attributable targets. Recent and current targets include Evercore ISI at $15, JonesTrading at $8 (lowered from $13), Wells Fargo at $6, Ladenburg Thalmann at $6, Baird at $6, H.C. Wainwright at $5, Guggenheim at $5, Clear Street at $4.60, RBC Capital at $4, Chardan Capital at $4, and Barclays at $3. The resulting average is roughly $6.05, which rounds to $6. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.

The dispersion is unusually wide. Bullish analysts argue the gene-editing platform and EDIT-401 data justify a premium, while cautious voices, including the Hold-rated RBC Capital and Barclays, emphasize execution risk and dilution. Independent aggregators show similar but not identical figures: S&P Global's survey points to an average near $6.10 across 13 analysts, while shorter-window averages range from about $5.20 to $7.20 depending on which targets and time period are included. Recent actions have leaned positive, with Wells Fargo upgrading the stock to Overweight and Guggenheim upgrading it to Buy in the second half of 2026.

Current Market Position and Path Toward the Target

EDIT last closed at $1.71 on November 19, 2026, near the lower end of a 52-week range of roughly $1.66 to $3.94. Reaching $6 would require a gain of about 250%, which is a very large move by any standard and far beyond a typical single-stage catalyst for a small-cap biotech.

The company reported third-quarter 2026 results on November 9, 2026, posting a net loss of about $23.4 million, or $0.15 per share, beating expectations, with revenue of roughly $10.4 million, up about 37% year over year. It ended the period with cash near $190 million and a market capitalization in the mid-$200-million range. A path to $6 would likely require a combination of positive EDIT-401 clinical data, continued cost discipline, and a broader re-rating of gene-editing stocks — not simply a single quarter of improvement.

What Could Support a Move Toward the Target

Several factors could support a recovery. The company's financial losses have narrowed materially — a nine-month 2026 net loss of about $67 million versus roughly $154 million a year earlier — and its cash position has improved. Analysts at TD Cowen and Evercore ISI have cited promising EDIT-401 data and a strengthened cash runway as reasons for constructive ratings. Recent upgrades from Wells Fargo and Guggenheim, alongside target increases from Chardan Capital, indicate that sell-side sentiment has been firming even as the share price has declined.

The lead program addresses a large, underserved population in hyperlipidemia, and positive in vivo gene-editing data would validate the broader platform. As a high-beta (about 2.1) small-cap, EDIT could also benefit disproportionately if risk appetite in the biotechnology sector improves.

What Could Prevent the Target From Being Reached

The obstacles are substantial. EDIT remains pre-commercial, with revenue derived almost entirely from collaborations, and it is still burning cash at a significant rate. Dilution is a persistent risk: shares outstanding grew by roughly 38% over the past year. A high short interest, estimated at over 20% of the float in some reports, adds volatility and reflects genuine skepticism.

Regulatory and clinical timelines for gene-editing therapies are long and uncertain, and competition from peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics is intense. If EDIT-401 data disappoint, or if the company needs to raise capital at depressed prices, the stock could remain under pressure regardless of analyst targets.

Technical Levels and Market Structure

EDIT is trading below both its 50-day moving average near $2.54 and its 200-day moving average near $2.70, reflecting a damaged long-term trend. The 52-week high of $3.94 is the first major resistance zone, followed by the psychological $5.00 level, then the $6.00 area where several analyst targets cluster. On the downside, the 52-week low near $1.66 is the critical support level; a sustained break below it would undercut the bullish case.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms apply different assumptions, and a handful of targets in this set are older and may not yet reflect the latest data. Investors should watch EDIT-401 clinical updates and preclinical readouts, quarterly earnings and cash-burn trends, any financing or partnership announcements, analyst target revisions, and broader sector sentiment toward gene editing.

Monitoring with AI Daily Buy/Sell Signals

In my experience following volatile names like this, automated tools can provide an extra layer of discipline. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap like EDIT, this kind of automated monitoring can help traders spot shifting momentum and manage risk more efficiently than manual chart review. Traders can use the signals to discover opportunities, monitor existing positions, and identify changing trends. The system updates in real time, which is particularly useful when clinical or financing news hits suddenly.

Final Assessment

Reaching $6 from $1.71 would require roughly a 250% advance, a very large move that would likely depend on a decisive positive catalyst such as compelling EDIT-401 data or a major partnership. The analyst range of about $3 to $15 illustrates how wide the range of credible outcomes is, with the average near $6 sitting far above the current price. Supportive factors — narrowing losses, a stronger cash position, and recent upgrades — are real but are offset by dilution risk, heavy cash burn, high short interest, and clinical uncertainty. The $6 level is best understood as an average of what analysts believe the stock could be worth, not a forecast of near-term direction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EDIT

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 78 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 121 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.596). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
87
Web
https://www.editasmedicine.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.